
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's strong financial position is highlighted by a substantial cash reserve of approximately €16.7 billion, which provides a solid foundation for ongoing research and development activities. The company's oncology pipeline demonstrates significant potential, particularly with the promising Phase 3 DYNASTY-Breast02 trial for BNT323, indicating a positive trajectory in its drug development efforts. Additionally, the encouraging data from preclinical models for its LP.8.1-adapted COVID-19 vaccine indicates improved immune responses against multiple SARS-CoV-2 sublineages, further reinforcing BioNTech's innovative capabilities in vaccine development.
Bears say
BioNTech is facing several significant risks that contribute to a negative outlook, including potential negative clinical data across multiple oncology programs, slow market uptake of its products, and challenges in advancing its pipeline in a timely manner. The company reported a net loss per diluted share of €0.12 for the third quarter of 2025 and projects a full-year net loss of €3.99 per diluted share, indicating ongoing financial challenges. Furthermore, investor focus is likely to be hindered by evolving dynamics in the COVID-19 vaccine market, particularly due to regulatory pressures in the U.S., overshadowing the potential of its oncology portfolio.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares